News & Updates

Luspatercept bests epoetin alfa in head-to-head LR–MDS-related anaemia trial

17 Jul 2023 by

In the treatment of anaemia in patients with lower-risk myelodysplastic syndromes (LR-MDS), luspatercept seems to perform better than epoetin alfa at restoring iron stores, according to the interim results of the open-label phase III COMMANDS trial.

Luspatercept bests epoetin alfa in head-to-head LR–MDS-related anaemia trial

17 Jul 2023

Does the type of facility affect outcomes in patients with Merkel cell carcinoma?

17 Jul 2023

Treatment of Merkel cell carcinoma (MCC), a rare neuroendocrine skin cancer with high mortality and rising incidence, at either an academic or a high-volume centre tends to lead to better patient survival, as shown in a recent study.

Does the type of facility affect outcomes in patients with Merkel cell carcinoma?

17 Jul 2023

SGLT2 inhibitors tied to kidney benefits, reduced MACE risk

17 Jul 2023 by

Treatment with sodium-glucose lowering co-transporter 2 inhibitors (SGLT2i) helps arrest the decline in estimated glomerular filtration rate (eGFR) and is associated with a lower risk of adverse kidney events among adults with diabetes, irrespective of baseline albuminuria status, as shown in a study presented at the recent ADA 2023.

SGLT2 inhibitors tied to kidney benefits, reduced MACE risk

17 Jul 2023

Warning against concomitant use of VPA-carbapenem ineffective: study

17 Jul 2023

Simultaneous use of carbapenem and valproic acid (VPA) is not common, but the best practice advisory (BPA) that warns clinicians of an interaction between these two drugs leading to significant declines in VPA levels does not appear to work in 63 percent of instances, reveals a study.

Warning against concomitant use of VPA-carbapenem ineffective: study

17 Jul 2023

Meal replacement trumps food-based diet for improving CV risk factors in obese adults

17 Jul 2023 by

In the secondary and exploratory analyses of the OPTIWIN trial, meal replacement (MR) outdid a food-based (FB) regimen in improving cardiometabolic risk in adults with obesity.

Meal replacement trumps food-based diet for improving CV risk factors in obese adults

17 Jul 2023

Mepolizumab does little to improve dysphagia symptoms

17 Jul 2023

Mepolizumab does not appear to reduce the symptoms of dysphagia as compared with placebo in the treatment of individuals with eosinophilic oesophagitis (EoE), although the drug helps reduce eosinophil counts and endoscopic severity, according to a study.

Mepolizumab does little to improve dysphagia symptoms

17 Jul 2023

Neutrophils may pave the way for new-generation immunotherapy

17 Jul 2023 by

Neutrophils play a crucial role in suppressing or promoting tumour growth. Gene-edited neutrophils with SMAD3 deletion enhance neutrophil-mediated antitumour activity in non-small-cell lung cancer (NSCLC), according to researchers from the Chinese University of Hong Kong (CUHK).

Neutrophils may pave the way for new-generation immunotherapy

17 Jul 2023

Fewer migraine days with dual therapy

17 Jul 2023 by

Combination therapy with an anti-CGRP* monoclonal antibody (mAB) and onabotulinumtoxinA may be more effective than either therapy in patients with chronic migraine, according to a new study.

Fewer migraine days with dual therapy

17 Jul 2023

Aquablation beneficial in men with urinary retention

16 Jul 2023

Aquablation therapy appears to lead to spontaneous voiding in men with urinary retention, regardless of preoperative urodynamic findings, according to a study.

Aquablation beneficial in men with urinary retention

16 Jul 2023

Bezlotoxumab prevents CDI recurrence in immunocompromised patients

16 Jul 2023

Treatment with bezlotoxumab results in a significant decrease in recurrent Clostridioides difficile infection (CDI) in a cohort of immunocompromised patients and transplant recipients, reports a study.

Bezlotoxumab prevents CDI recurrence in immunocompromised patients

16 Jul 2023

News & Updates

Filter by Specialty:

Specialty:

Luspatercept bests epoetin alfa in head-to-head LR–MDS-related anaemia trial

Luspatercept bests epoetin alfa in head-to-head LR–MDS-related anaemia trial

Does the type of facility affect outcomes in patients with Merkel cell carcinoma?

Does the type of facility affect outcomes in patients with Merkel cell carcinoma?

SGLT2 inhibitors tied to kidney benefits, reduced MACE risk

SGLT2 inhibitors tied to kidney benefits, reduced MACE risk

Warning against concomitant use of VPA-carbapenem ineffective: study

Warning against concomitant use of VPA-carbapenem ineffective: study

Meal replacement trumps food-based diet for improving CV risk factors in obese adults

Meal replacement trumps food-based diet for improving CV risk factors in obese adults

Mepolizumab does little to improve dysphagia symptoms

Mepolizumab does little to improve dysphagia symptoms

Neutrophils may pave the way for new-generation immunotherapy

Neutrophils may pave the way for new-generation immunotherapy

Fewer migraine days with dual therapy

Fewer migraine days with dual therapy

Aquablation beneficial in men with urinary retention

Aquablation beneficial in men with urinary retention

Bezlotoxumab prevents CDI recurrence in immunocompromised patients

Bezlotoxumab prevents CDI recurrence in immunocompromised patients